Renowned international expert in medicine Dr. Charles Alessi joins Nightingale Health UK as Chief Medical Officer

Nightingale Health Plc

Press release

6 November 2024 at 09:45 a.m. (EET)

 

Nightingale Health, a pioneer in disease risk detection and preventative health has appointed internationally recognised expert in medicine Dr. Charles Alessi as Chief Medical Officer of Nightingale Health UK.

 

Dr. Charles Alessi is a physician with more than 35 years of experience in all aspects of policy and clinical practice in the United Kingdom, Northern Ireland and globally. Alessi’s experience includes key positions in some of the world leading organisations in the industry, such as acting as a member of the World Health Organisation’s expert panels in neurosciences and dementia risk deduction, Global Chief Clinical Officer at Healthcare Information and Management Systems Society (HIMSS), Senior Advisor to Public Health England and Chairman of National Association of Primary care (NAPC) in the UK. He is also currently advising the chief executive of the International Association of Public Health Institutes (IANPHI) as well as the new public health agency Weqaya in the Kingdom of Saudi Arabia. In these capacities, he has led initiatives around preventative health working at the most senior levels both with governments and corporations.

 

Dr. Charles Alessi has recently been appointed as associate lecturer in medicine at the medical faculty at Anglia Ruskin University in England and as adjunct research professor in Biostatistics and Epidemiology at the University of Western Ontario, Canada. He sits on advisory board of medical technology companies and has published very widely in academic popular journals, as well as co-authoring a book on helping people better manage their risk factors in reducing their risk of cognitive decline.

 

At Nightingale Health, Dr. Alessi will have a key strategic position in bringing the benefits of the company’s technology available to customers in the United Kingdom as well as supporting Nightingale Health’s global efforts.

 

“I am very excited at the prospect of joining Nightingale Health as their Chief Medical Officer and the timing could not be better. Healthcare systems in countries globally are moving from activity based to prevention-based systems and Nightingale Health, as a world leader in personalised prevention, is in prime position to help them achieve this. As someone who has spent the last few years talking about prevention, I feel I am coming home.” says Dr. Charles Alessi.

 

“We are delighted and honoured to have Charles joining the global Nightingale family. His unique international experience and expertise in preventative healthcare is truly impressive and I’m confident that our collaboration will greatly help us in our mission to create more sustainable healthcare systems around the world with our technology.” says Teemu Suna CEO and Founder of Nightingale Health.

 

 

For further information, please contact:

Teemu Suna, CEO
[email protected]

 

About Nightingale Health

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/